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Distribution of free and protein-bound Cbl in LMBRD1-transfected control and patient cell lines. Fibroblasts from two controls, 
two patients with cblF defect, patient 1 and patient 2, which were transfected with wildtype LMBRD1 cDNA, were incubated 
in a medium containing [57Co]cyanococalamin, and cell homogenates were subjected to fast protein liquid chromatography 
(See Figure 1 for comparison). Transfection of control cell lines did not affect their cobalamin distributions. Transfection of 
both cblF cell lines with wildtype LMBRD1 cDNA (LMBRD1-wt) corrected the cobalamin binding pattern. Transfection of both 
cblJ cell lines with wildtype LMBRD1 cDNA did not correct the cobalamin binding pattern. All results are single determinants 
expressed as % of total radioactivity in all fractions in each experiment. TC-Cbl: TC-bound Cbl; Free Cbl: free form of Cbl; 
Enzyme-Cbl: enzyme-bound Cbl. 
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Supplementary Figure 2 
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The lower cofactors synthesis following amino-acid substitutions in the putative ATPase region does not result from a 
destibilizing effect or loss of expression. Immortalized fibroblasts were transfected transiently with constructs coding for 
ABCD4 wild type (wt) and mutant alleles tagged with red fluorescent protein (RFP) by electroporation. 
Rescue of function was detected by the assay of adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl) synthesis. 
Transfection with a construct coding for untagged wild type (ABCD4-wt) was used as negative control.Columns represent 
the mean and error bars the s.d. of results from 6 (RFP-tagged) and 8 (untagged) replicate experiments with single 
determinations.Cell lysates were subjected to SDS-PAGE and immunoblotted with anti-RFP and anti-actin antibodies.  
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Supplementary Table 1. Biochemical findingsa in cultured skin fibroblasts of both cblJ patients, cblF patients and unaffected controls  
__________________________________________________________________________________________________________________________________________________ 
       
 Patient 1 Patient 2 cblF patients Control values 
__________________________________________________________________________________________________________________________________________________ 
Total uptake of [57Co]cyanocobalamin (pg/mg protein) and synthesis of  MeCbl and AdoCbl (% distribution of total cobalamins) b: 
Total uptake 214 (160 – 300) 163 (93.9 – 291) 127 (100 - 182) n=5 71 (19-142) n=32 
MeCbl % 0.8 (0.2 – 1.3)  2.3 (1.5 – 2.8) 5.0 (4.0 - 5.5) n=5 60 (48-78) n=32 
AdoCbl % 0 (0 – 0.1)  0.5 (0.3 – 0.8) 3.6 (3.0 - 4.3) n=5 14 (6.9-30) n=32 
CNCbl % 94 (92 – 97)  87 (83 – 90) 84 (83 - 85) n=5 8.7 (3.3-18) n=32 
OHCbl % 4.4 (2.8 – 5.7)  9.1 (6.6 – 12) 7.5 (7.0 - 8.0) n=5 16 (7.3-25) n=32 
 [14C]propionate incorporation (nmol/mg protein/16h): 
basal medium 0.96 (0.63 – 1.61) 1.63 (1.23-1.86) 1.11 (0.74- 1.53) n=5 11.7 (6.37 – 18.5) n=13 
medium+OHCbl c 5.83 (5.00 – 7.46) 3.49 (3.06-4.19) 10.0 (8.06-15.7) n=5 12.4 (5.15- 21.4) n=13 
[14C]formate incorporation into methionine (nmol/mg protein/16h): 
basal medium 0.08 (0.06 – 0.11) 0.45 ( 0.33 – 0.66) 0.20 (0.04-0.58) n=5 2.22 (1.11– 3.90) n=24 
medium+OHCbl c 2.17 (1.84 – 2.49) 1.13 (0.75 – 1.79) 1.82 (1.37-2.40) n=5 2.58 (1.31 – 4.88) n=24 
[14C]methylTHF incorporation (pmol/mg protein/18h): 
basal medium  40 (25 – 54)  32 (28 – 39)  43 (30 – 72) n=11 156 (79 – 221) n=5 
medium+OHCbl d 60 (48 – 67) 73 (63 - 86) 297 (59 - 654) n=11 371 (300 – 546) n=5 
__________________________________________________________________________________________________________________________________________________ 
a Values for the cblJ patients are the mean and range (in brackets) of results from 3 replicate experiments, and for cblF patients and controls the mean and range (in brackets) of 
activities from n different cell lines 
b MeCbl = methylcobalamin; AdoCbl = adenosylcobalamin; OHCbl = hydroxocobalamin; CNCbl = cyanocobalamin; small amounts of further un-identified 57Co-labelled compound were 
additionally detected (not shown) 
c Parallel cell cultures were incubated for 3 days in medium supplemented with OHCbl (0.7 µmol/L), or d for 18 hours in medium supplemented with OHCbl (1.5 µmol/L) prior the assay. 
Nature Genetics: doi:10.1038/ng.2386
Supplementary Table 2. Mutation analysis of TPRG1, LRP2 and ABCD4 in patient 1 and family members. Nucleotide 
numbering is based on the cDNA sequence with +1 corresponding to the A of the ATG translation initiation codon; WT, 
wild type. Patient 1 is born to parents with no history of consanguinity and has an asymptomatic sibling. Exome 
sequencing identified three candidate genes with compound heterozygous mutations in each. Both mutations in TPRG1 
were detected in the paternal DNA by Sanger sequencing, meaning that they were present in cis and passed down to 
the patient on a single allele. In fact, the c.422G>T mutation did not affect the gene product because the upstream 
c.183_192del (p.Tyr61*) mutation created a premature stop codon. Since the patient must have inherited the maternal, 
wild type allele, TPRG1 mutations cannot be causative of the patient’s disorder. For LRP2, the father and mother were 
heterozygous for each of the mutant alleles, but the asymptomatic sibling was found to be a compound heterozygote. 
Therefore, LRP2 mutations are also not responsible for the defect. For ABCD4, the father and mother were again 
heterozygous for each of the mutant alleles, c.956A>G and c.1746_1747insCT, respectively. However, unlike LRP2, the 
sibling did not carry either of the mutations. This pinpointed ABCD4 as the disease-causing gene.  
 
 TPRG1 LRP2 ABCD4 
Father c.183_192del c.422G>T WT c.10937G>A c.956A>G WT 
Mother WT WT c.3932G>A WT WT c.1746_1747insCT 
Sibling  WT WT c.3932G>A c.10937G>A WT WT 
Patient c.183_192del c.422G>T c.3932G>A c.10937G>A c.956A>G c.1746_1747insCT 
Nature Genetics: doi:10.1038/ng.2386
 
Supplementary Table 3. Transfer of normal human chromosome 14 into fibroblasts of cblJ patient 2 rescues cobalamin cofactor synthesis. Single normal human chromosomes, 
tagged with a hygromycin resistance gene, were serially transferred into immortalized fibroblasts of the cblJ patient 2 by microcell-mediated chromosome transfer29, and the rescue 
of function was detected by the assay of synthesis of the cobalamin cofactors, methylcobalamin (MeCbl) and adenosylcobalamin (AdoCbl), from [57Co]cyanocobalamin. 30 
hygromycin resistant colonies obtained after transfer of normal chromosome 14 showed rescue of AdoCbl and MeCbl synthesis whereas 36 colonies carrying twelve other 
transferred chromosomes (one colony with chromosome 6, 15, 22 and X, two colonies with chromosomes 2, 11 and 21, three with chromosomes 5 and 20, five with chromosome 
8, six with chromosome 7 and eight with chromosome 3) showed no rescue. For comparison distribution of cobalamins is shown for immortalized cblJ patient 2 cells (recipient 
cells) and an immortalized control fibroblast cell line (both without chromosome transfer) and for 23 mouse A-9/human single chromosome hybrid cell lines (donor cell lines) each 
with a different single human chromosome28. Values are the mean ± s.d. and the range in brackets of results from replicate experiments with single determinations (recipient cells 
and a control cell line) or of results in different cell lines (colonies, mouse human hybrid cell lines) from experiments with single determinations. 
_____________________________________________________________________________________________________________________________________________  
 Cobalamin distribution, % of total cobalamins* 
Cell line MeCbl AdoCbl CNCbl OHCbl 
_____________________________________________________________________________________________________________________________________________  
Colonies obtained after transferring normal human single chromosomes into cells of cblJ patient 2: 
30 cblJ colonies with normal human chromosome 14  49 ± 9 (34-64) 15 ± 5 (6-29) 13 ± 5 (5 - 24) 20 ± 6 (10-37) 
36 cblJ colonies with 12 other normal human chromosomes 2 ± 1 (0.6-6) 0.8 ± 0.5 (0-2) 91 ± 2 (84 - 95) 5 ± 1 (2-9) 
 
Recipient, donor and control cell lines without chromosome transfer: 
cblJ (patient 2) cells (5 experiments) 1 ± 0.4 (0.8-2) 0.7 ± 0.2 (0.4-0.9) 92 ± 1 (91-94) 5 ± 0.5 (5-6) 
Control cell line (7 experiments) 49 ± 11 (33-68) 17 ± 4 (10-22) 13 ± 5 (6-22) 18 ± 5 (12-28) 
23 different mouse human monochromosomal hybrid cell lines 30 ± 10 (9-46) 24 ± 6 (14-36) 17 ± 9 (6-46) 29 ± 4 (22-38 
_____________________________________________________________________________________________________________________________________________  
*MeCbl = methylcobalamin, AdoCbl = adenosylcobalamin, CNCbl = cyanocobalamin, OHCbl = hydroxocobalamin; small amounts of further un-identified 57Co-labelled compound 
were additionally detected (not shown) 
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 Supplementary Table 4. Filtering strategy for the called variants in patient 2. Using MAQ and SAMtools, in total 
417198 variations were found. After filtering for a minimal phred-like consensus quality score >15 and minimal 
coverage of 4 reads, 164578 variations remained. A stringent filter step discarding known variations using dbSNP 
and 1000 genomes data reduced the list to 25418 variations of which 729 covered chromosome 14. Further 
filtering for allele frequency > 25%, protein changing variations or variations +/- 10 nts close to the 3’/5’ splice 
sites reduced the list to 9 candidate variations.  
 
 Filtering step Count 
Total count of variations 417198 
Minimal quality (>4 reads; Qual>15) 164578 
Not in dbSNP and 1000genomes 25418 
On chromosome 14 729 
Protein Change or within 10 bp 3'SS/5'SS + Allelfreq > 25%  9 
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Supplementary Table 5. Candidate gene list for patient 2 based on whole exome sequencing and stringent filtering. In total 9 candidate variations were detected. Four of them 
were found to be rare variants by searching the Exome Variant Server (NHLBI Exome Sequencing Project (ESP), Seattle, WA (URL: http://snp.gs.washington.edu/EVS/) [Sept 
2011]). The FOXN3 variant was predicted to be benign by the Polyphen software. The splice site variant in GALC is not very likely to be pathogenic because it does not affect the 
conserved splice positions and also is embedded in an poly-A stretch leading to an A(11) to A(10) shortening. The remaining variations are a 2-bp deletion in TRIP11 resulting in a 
premature termination codon and two different mutations in the gene  ABCD4: Gly486Cys which was predicted as possibly damaging (Polyphen) and a splice site mutation 
affecting the highly conserved position +1. This pinpointed ABCD4 as the disease-causing gene. 
 
Chr. g.DNA_change Qual. Depth 
Allele
Freq. 
NHLBI Exome 
Variant Server (MAF) Gene CCDS c.DNA_change Prot_Change Polyphen 
14 74756186C>A 255 120 38  ABCD4 CCDS9828.1 c.1456G>T Gly486Cys possibly damaging 
14 74763035C>A 177 39 46  ABCD4 CCDS9828.1 c.542+1G>T   
14 96752219G>A 255 131 41 0,0007 ATG2B CCDS9944.2 c.6110C>T Pro2037Leu probably damaging 
14 24113634A>G 255 253 44 0,007 DHRS2 CCDS41927.1 c.557A>G Asn186Ser  
14 89647123G>A 255 84 46  FOXN3 CCDS41977.1 c.839C>T Ala280Val benign 
14 88417096delA 678 148 76  GALC CCDS9878.2 c.1162-4delT   
14 105609325C>T 98 27 63 0,003 JAG2 CCDS9998.1 c.3424G>A Gly1142Arg possibly damaging 
14 64625344T>C 255 200 43 0,02 SYNE2 CCDS9761.2 c.15794T>C Val5265Ala possibly damaging 
14 92471348AGdel 11770 389 40  TRIP11 CCDS9899.1 c.2972_2973delCT Ser991*  
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Supplementary Table 6. Statistical significance (p -values) of rescue of function presented in Fig 3. Differences 
in adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl) synthesis were evaluated after transient 
transfection of immortalized fibroblasts with different wild type (wt) and ABCD4 mutant constructs using 
transfection with an empty pTracer vector (vector only) as negative control. 
The statistical significance was tested by using the unpaired t-test (two tailed), with Welch’s correction for unequal 
variances, and GraphPad Prism software (version 4). P-values less than 0.05 were considered to indicate 
statistical significance 
__________________________________________________________________________  
Cell line         Comparison between p-values for synthesis of 
transfected construct 1     & construct 2 AdoCbl MeCbl  
__________________________________________________________________________  
Patient 1 vector only ABCD4-wt p =  0.005 0.0002 
Patient 2 vector only ABCD4-wt p =  0.0009 0.010 
Patient 1 ABCD4-wt ABCD4-c.956A>G p =  0.016 0.0003 
Patient 2 ABCD4-wt ABCD4-c.956A>G p =  0.001 0.029 
Patient 1 ABCD4-wt ABCD4-c.1456G>T p =  0.005 0.0002 
Patient 2 ABCD4-wt ABCD4-c.1456G>T p =  0.0007 0.013 
Patient 1 vector only ABCD4-c.1456G>T p =  1.00 0.79 
Patient 2 vector only ABCD4-c.1456G>T p =  0.42 0.007* 
Patient 1 vector only LMBRD1-wt p =  0.57 0.79 
Patient 2 vector only LMBRD1-wt p =  0.38 0.21 
cblD vector only ABCD4-wt p =  0.42 0.98 
cblF vector only ABCD4-wt p =  0.005 <0.0001 
__________________________________________________________________________  
* significant but very low increase from 5-9% to 11-16% of the mean ABCD4-wt values.  
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Supplementary Table 7. Functional peroxisomes are not required for intracellular synthesis of the cobalamin cofactors adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). 
Three fibroblast cell lines with severe deficiency of peroxisomal biogenesis and deficient import of catalase due to homozygosity for a mutation in different PEX genes and one 
control cell line (experimental control) were incubated for 4 days in a medium containing 10% human serum and 25 pg/ml [57Co]cyanocobalamin. Then total uptake of 
[57Co]cyanocobalamin and cobalamin coenzyme synthesis were estimated as described under Methods.  
______________________________________________________________________________________________________________________________________________ 
Cell line  Total uptake§ Distribution of cobalamins, % of total cobalamins§ 
genotype (homozygous)  pg/mg protein OHCbl                  CNCbl AdoCbl MeCbl unknown 
______________________________________________________________________________________________________________________________________________ 
Cell line 1: mutation in PEX1  
c.2097_2098insTC>T / p.872* 63.1 12.1, 10.9 5.1, 6.4 11.4, 11.7 69.7, 69.6 1.7, 1.5 
 
Cell line 2: mutation in PEX2   
c.115C>T / p.Gln39*   90.2 10.2, 11.4 7.3, 7.1 13.3, 12.8 67.2, 66.4 2.0, 2.3 
 
Cell line 3: mutation in PEX6  
c.685_686insAG / p.Ser232Hisfs*15 85.0 13.4, 12.7 5.8, 4.9 14.2, 13.6 64.7, 66.7 1.9, 2.1 
 
 
Experimental control  72.1 15.2, 16.8 6.8, 8.0 8.8, 10.9 67.1, 61.6 2.1, 2.7 
______________________________________________________________________________________________________________________________________________ 
32 reference cell lines: mean  70.8 15.6 8.7 14.1 60.3 1.3   
  range  (18.7-142) (7.3-24.6) (3.3-18.3) (6.9-29.9) (47.7-78.5) (0.1-3.1) 
______________________________________________________________________________________________________________________________________________ 
§values obtained in PEX mutant cell lines and the experimental control are single determinations within one experiment 
OHCbl =hydroxocobalamin; CNCbl =cyanocobalamin; AdoCbl = adenosylcobalamin; MeCbl =methylcobalamin 
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Supplementary Note 
 
Case reports 
 
Patient 1 was born at 40 weeks gestation by emergency C-section for fetal distress. The birth weight was 2.565 
kg (1st centile), length was 47 cm (1st centile) with weight for height at the 23rd centile, head circumference was 
31.8 cm (<1st percentile). She had respiratory distress and required supplemental oxygenation by oxyhood. 
APGAR scores were 6 at 1 minute and 8 at 5 minutes. She was placed on antibiotics to treat a possible 
pneumonia because of an infiltrate seen on chest X-rays. She was noted to have hypotonia, lethargy, poor 
feeding, periodic breathing, and episodes of posturing. There was evidence of bone marrow suppression requiring 
red blood cells and platelet transfusions. Newborn screening showed an elevated C3 (propionyl) carnitine at 11.9 
(reference<5) µmol/L (the newborn screening program did not have a cut-off for low methionine). Initial laboratory 
testing failed to show metabolic or lactic acidosis or ketonuria. The infant was started on hydroxocobalamin and 
transferred to a tertiary facility at 2 weeks of age. On admission, plasma amino acids indicated low methionine of 
5 µmol/L (reference 17-53), absent free homocysteine, elevated total plasma homocysteine at 20 µmol/L 
(reference <12). The serum methylmalonic acid was 20.25 µmol/L (reference <0.4). Urine organic acids indicated 
an isolated increase in methylmalonic acid at 154 mmol/mol creatinine (reference <5). Blood counts were 
significant for neutropenia (absolute neutrophil count 0.3 K/µL, reference 1.5-10 K/µL), thrombocytopenia (55-106 
K/µL, reference 150-400 K/µL), while the previous anemia had resolved with transfusions. The patient was started 
on Colony Stimulating Factor that corrected neutrophil and platelet counts. The child was continued on a regular 
diet (breast milk), hydroxocobalamin (2 mg per day) IM injections, methylcobalamin (2 mg p.o. twice a day), 
methylTHF (3 mg twice a day), pyridoxal phosphate (35 mg twice a day), betaine (100 mg/kg per day divided into 
3 doses). With this treatment, the plasma amino acids normalized completely, as did total plasma homocysteine 
and serum methylmalonic acid levels. Additional problems identified were a heart murmur (caused by 2 small 
atrial level shunts that were not significant hemodynamically, and were no longer present at 1 year of age) and 
gastroesophageal reflux. Brain imaging and spectroscopy were unremarkable. Clinically, she stopped requiring 
oxygen, started eating orally and was discharged home at 36 days of age.  
Following discharge from the hospital, the patient did well with no other hospitalizations, except one at 7 months 
of age for the elective repair of a left inguinal hernia. From a developmental standpoint, the child started walking 
unassisted at 12 months, spoke her first word at 15 months and, at two years of age speaks about 30 words 
without sentences. She is being followed by a speech therapist. At 2 years of age, she has an unrestricted diet 
and growth parameters are at the 5th percentile. The therapy consists of hydroxocobalamin (2.5 mg IM twice per 
week), methylcobalamin (2 mg p.o. twice a day), methylTHF (3 mg twice a day), pyridoxal phosphate (35 mg 
twice a day). Betaine was stopped at 6 months of age.  With this therapy, plasma amino acids and total plasma 
homocysteine are persistently within the reference range, while methylmalonic acid is mildly elevated in serum 
(0.68-1.45 µmol/L, reference <0.4 µmol/L) and urine (6-13 mmol/mol creatinine, reference <5 mmol/mol 
creatinine). 
 
 
Patient 2 was born as the second child of non-consanguineous German parents at 40 weeks of gestation by C-
section because of a discrepancy between the maternal pelvis and the fetal head circumference. Birth weight was 
3040 g (12th centile), length 48 cm (10th centile), head circumference 35.5 cm (50th centile), and the APGAR 
scores were 9 and 10 at 5 and 10 minutes, respectively. On the second day of life he had raised body 
temperature and tachypnea, and sepsis therapy was started. He was referred to a tertiary care centre, where 
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physical examination revealed hypertelorism, micrognathia, wide inter-mamillary distance, a bell-shaped thorax, 
horizontal ribs and short extremities. Cardiac catheterization demonstrated an atrial septal defect, coarctation of 
the aorta, a small left ventricle, an enlarged right ventricle and pulmonary hypertension. He was treated with 
antibiotics, diuretics and digoxin. Because of feeding difficulties he required a nasogastric tube. 
Newborn screening was reported to be unremarkable. Laboratory testing revealed normocytic normochromic 
anemia with a haemoglobin level of 12 g/dl, mean corpuscular volume 101fl, and mean corpuscular hemoglobin of 
35.2 pg. He received two red blood cell transfusions. Chromosome analysis revealed a normal male karyotype.  
The clinical course during the first months of life was complicated by feeding difficulties, generalized hypotonia 
and developmental delay. Cerebral ultrasound revealed mild cerebral atrophy at 4 months of age. Repeated 
cardiac catheterization at 6 months of age revealed increased narrowing of the aortic isthmus and a 
hemodynamically relevant type II atrial septal defect. Therefore, corrective surgery of the aorta and closure of a 
patent ductus arteriosus was performed. At the age of 13 months, Noonan syndrome was suspected because of 
failure to thrive, facial dysmorphism, developmental delay and cardiac anomalies. At this age, his weight was 
6400g (below 1st centile), length 64 cm (below 1st centile), and head circumference 43 cm (above 97th centile). 
Mutation analysis of the PTPN11 gene for Noonan syndrome did not reveal a mutation. Serum amino acids were 
reported as normal. Skeletal X-rays of pelvis, hand, knee and spine revealed a delayed bone age, but no specific 
skeletal anomaly. 
At the age of 16 months, methylmalonic aciduria was noted, plasma total homocysteine was 50 (reference <15) 
µmol/l, and plasma cobalamin was 815 pg/ml (reference 190-880 pg/ml). Fibroblast studies revealed findings 
consistent with the cblF defect. At the age of 18 months, he received his first dose of hydroxocobalamin, 1 mg 
intramuscularly. The homocysteine levels dropped to 15 µmol/l. Monthly injections with hydroxocobalamin were 
started. The patient showed some progress of his psychomotor development and started to speak two word 
sentences at the age of 20 months. At the age of 22 months, he had a bilateral inguinal hernia repair and a 
bilateral orchidopexia for cryptorchidism. At the age of 2 ½ years, he had a complicated febrile convulsion. At the 
age of 5 years, he was treated with hydroxocobalamin injections 1 mg every 4 to 5 weeks intramuscularly. He 
showed gradual progress in his psychomotor development, but was still underweight (13.0 kg, below 1st centile) 
and short (92 cm, below 1st centile).  
At the age of 7 years, he developed pneumococcal septic arthritis of the right hip, during an episode of 
neutropenia (leucocyte count 3700/µl, absolute neutrophil count 1300/µl), requiring surgery of the hip and 
prolonged systemic antibiotic therapy. The hospital course was complicated by a mediastinal hemorrhage 
(hemoglobin dropped to 7 g/dl, hematocrit 21%) and paresis of the right phrenic nerve, most likely caused by a 
dislocation of a central venous catheter. He therefore required a red blood cell transfusion. Intramuscular 
injections with hydroxocobalamin were continued at a dose of 1.0 mg every three weeks.  Currently, at the age of 
seven and a half years, levels of both plasma homocysteine (15.5 µmol/l ) and serum methylmalonic acid (134 
µg/l) remain elevated.  
 
 
Comparison with the cblF phenotype 
The findings in the two cblJ patients show similarities to these seen in the thirteen reported patients who fall into 
the cblF complementation class1. The cblF patients typically had elevations of both homocysteine and 
methylmalonic acid, although only elevated methylmalonic acid was described in the original patient. Most cblF 
patients were diagnosed in the first year of age, some following positive newborn screening, although one was not 
diagnosed until eleven years of age. Features seen in some cblF patients, and also seen in at least one of the two 
cblJ patients, include feeding difficulties, anemia and pancytopenia, unusual facial appearances, and congenital 
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heart defects. Thus, it would be hard to distinguish cblF and cblJ patients on clinical and laboratory grounds alone. 
A definitive diagnosis requires somatic cell complementation analysis and/or sequencing of the LMBRD1 and 
ABCD4 genes.  
 
1. Watkins D. & Rosenblatt D.S. Inherited Disorders of Folate and Cobalamin Transport and Metabolism. In 
C. Scriver et al (eds): Metabolic and Molecular Bases of Inherited Disease -- OMMBID. www.ommbid.com, 
New York, McGraw-Hill, Chap. 17, August, 2011. 
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